|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
|
PMPS: Pharmaceutical logistics have come under huge pressure throughout the COVID-19 pandemic. How do you feel the industry as a whole has dealt with the situation?
Marcel Kuijn: The outbreak of the pandemic has had an unprecedented impact on the industry. From one day to the other, airlines had to ground almost their entire passenger fleet and crucial logistical flows came to a halt. Immediately, you saw that the industry started to look for alternative solutions. On the airline side, this meant flying passenger aircrafts only with cargo, carrying cargo in cabin, and/or converting passenger aircraft to freighters. The industry has shown significant agility and
creativity, but it has also put pressure on the teams. They have had to
work hard to make this happen, and often in difficult circumstances due
to the restrictions in place.
an airline was that the quantity of dry ice used for the vaccine transport was higher than what we normally see. This meant that we had to make sure that we could transport large quantities in a safe way, whereby the sublimation rate of dry ice was a key factor.
Deciding between dry ice and other cold chain solutions has been a talking point during the pandemic, what are the benefits of using these methods for air cargo?
We have seen that, for the transportation of COVID-19 vaccines, a range of cold chain solutions are being used from 2-8°C temperature-controlled products to active and hybrid containers and dry ice. The deep-frozen temperatures required for some of the vaccines meant that there were not any other options than dry ice. Dry ice is a dangerous good, and requires specific measures to ensure safety on the ground and in the air. The main challenge we had to work on as an airline was that the quantity of dry ice used for the vaccine transport was higher than what we normally see. This meant that we had to make sure that we could transport large quantities in a safe way, whereby the sublimation rate of dry ice was a key factor.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss
Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO:
Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company
transforming the lives of patients through a novel class of in vivo
reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President
and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative
medicine, today announced that they have executed a collaborative
research agreement on in vivo regenerative medicine approaches to
address sensorineural hearing loss.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial-Specific Travel Programs as a Patient Retention Tool
For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >> |
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
|
